A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Pilaralisib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Exelixis; Sanofi
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2012 Planned End Date changed from 1 Jan 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 21 Jun 2012 Additional location (France) added as reported by European Clinical Trials Database.